Media Release

Basel, 23 September 2016

Museum Tinguely celebrates 20th anniversary Roche reaffirms continues dedication to the

The celebrates its 20th anniversary on Sunday 25 September. It was founded by Roche in 1996 in commemoration of the company's centenary. Roche has fully funded the operation and maintenance of the museum ever since. As well as exhibitions about Jean Tinguely and his associates, the museum has also staged a large number of internationally recognised special exhibitions. More than 2.5 million people have visited the Museum Tinguely since its establishment, underscoring both the great success and the importance of the museum in 's cultural landscape. In addition to serving as an exhibition venue, the museum has hosted the monthly Roche 'n' Jazz concert series for more than ten years.

"We are delighted that the Museum Tinguely is celebrating 20 successful years", said Jürg Erismann, Head of Roche's Basel/Kaiseraugst site. "Our continued strong dedication to the museum underscores Roche's commitment to the Basel site and reaffirms our engaged patronage of culture and the arts. The museum also represents a significant cultural enrichment for Basel's Wettstein district," Jürg Erismann emphasised.

The Museum Tinguely is celebrating its 20th anniversary with a big party. On the final day of the special exhibition "Michael Landy. Out of Order" museum visitors are invited to explore a wide variety of attractions relating to Jean Tinguely and Michael Landy in the museum and Solitude Park. Information about the anniversary event can be found on the museum website at www.tinguely.ch

About the Museum Tinguely The Museum Tinguely, founded in 1996 and dedicated to the work of the Swiss metal sculptor Jean Tinguely, is Roche's most substantial commitment to culture. In addition to its permanent exhibition of the machine and graphic works of Jean Tinguely, who died in 1991, the museum also hosts special exhibitions that give an insight into the art and artists who influenced and were associated with Tinguely, kinetic art and 20th and 21st-century art. Current and past exhibitions have been dedicated to contemporaries of Tinguely such as Niki de Saint Phalle, Yves Klein and Eva Aeppli; to role models such as Marcel Duchamp, Kurt Schwitters and Max Ernst; and to more recent trends in that highlight Tinguely's

F. Hoffmann-La Roche Ltd 4070 Basel Group Communications Tel. +41 61 688 88 88 Roche Group Media Relations www.roche.com

1/3

continuing relevance for a younger generation of artists. Further information on the Museum Tinguely can be found on its website www.tinguely.ch

About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations

2/3

Phone: +41 -61 688 8888 / e-mail: [email protected] - Nicolas Dunant (Head) - Catherine Dürr - Ulrike Engels-Lange - Karsten Kleine - Anja von Treskow

3/3